Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
79.00
-0.45 (-0.57%)
Official Closing Price
Updated: 4:15 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
December 09, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
December 08, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
December 07, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer
December 06, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations
November 29, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer
November 28, 2022
From
Arcus Biosciences
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
November 15, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
November 11, 2022
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Via
MarketBeat
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
November 03, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
November 02, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease
November 01, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Third Quarter 2022 Financial Results
October 27, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities
October 24, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
October 20, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022
October 18, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
October 17, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
October 17, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022
October 13, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer
October 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
October 06, 2022
Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing...
Via
FinancialNewsMedia
Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product
October 03, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
September 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Completes Acquisition of MiroBio
September 20, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
September 16, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
September 16, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
September 15, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity
September 13, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study
September 07, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
September 06, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status
September 04, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.